MacroGenics (MGNX) Earnings Analysis

MacroGenics (MGNX) next reports earnings on 2026-08-13, consensus EPS 0.02583 USD. Last quarter (2026-03-09) it beat with EPS -0.22 USD vs -0.42 USD est (+47.6%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -3.91.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does MGNX next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate0.02583 USD
Revenue estimate0.07B

MGNX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-09-0.22 USD-0.42 USD+47.6%Beat
2025-11-120.27 USD-0.48 USD+156.3%Beat
2025-08-14-0.57 USD-0.59 USD+3.4%Beat
2025-03-20-0.25 USD-0.23 USD-8.7%Miss

Beat rate: 3/4 (75%) over reported quarters with consensus data.

MGNX valuation and analyst view

Trailing P/E-3.91
Trailing EPS-1.10888 USD
Price / book12.87
Dividend yield0.00%
Market cap0.28B
Analyst consensusBuy (12 buy / 9 hold / 1 sell)
Avg price target6 USD

Related research pages

Frequently asked questions

When is MacroGenics (MGNX)'s next earnings date?

MacroGenics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of 0.02583 USD and revenue estimate of 0.07B.

Did MGNX beat earnings last quarter?

In its 2026-03-09 report, MGNX posted EPS of -0.22 USD versus a -0.42 USD estimate — a beat of 47.6%.

What is MGNX's earnings track record?

Over the last 4 reported quarters with consensus data, MGNX beat estimates 3 times (75%).

What is MGNX's current P/E ratio and EPS?

MGNX trades at a trailing P/E of -3.91 on trailing EPS of -1.1088769732534927 USD.

What do analysts rate MGNX?

Analyst consensus is "Buy" across 22 ratings (0 strong buy, 12 buy, 9 hold, 1 sell, 0 strong sell). Average 12-month price target: 6 USD.